A second phase III trial of olmutinib (BI 1482694) for the treatment of non-small cell lung cancer

Trial Profile

A second phase III trial of olmutinib (BI 1482694) for the treatment of non-small cell lung cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Olmutinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2016 New trial record
    • 05 Jun 2016 According to a Boehringer Ingelheim media release, this is one of the two phase III trials expected to be initiated in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top